TY - JOUR
T1 - Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis
AU - McKown, Kevin M.
AU - Carbone, Laura D.
AU - Kaplan, Stanley B.
AU - Aelion, Jacob A.
AU - Lohr, Kristine M.
AU - Cremer, Michael A.
AU - Bustillo, Juan
AU - Gonzalez, Miguel
AU - Kaeley, Gurjit
AU - Steere, Elaine L.
AU - Somes, Grant W.
AU - Myers, Linda K.
AU - Seyer, Jerome M.
AU - Kang, Andrew H.
AU - Postlethwaite, Arnold E.
PY - 1999/6
Y1 - 1999/6
N2 - Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.
AB - Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.
UR - https://www.scopus.com/pages/publications/0033000532
UR - https://www.scopus.com/pages/publications/0033000532#tab=citedBy
U2 - 10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U
DO - 10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U
M3 - Article
C2 - 10366113
AN - SCOPUS:0033000532
SN - 0004-3591
VL - 42
SP - 1204
EP - 1208
JO - Arthritis and Rheumatism
JF - Arthritis and Rheumatism
IS - 6
ER -